https://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.png00Rebecca Mercerhttps://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.pngRebecca Mercer2019-07-19 11:19:262019-07-19 11:36:3868 Oncology Drug Market: A High-Growth, High-Price Therapeutic Area
https://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.png00Rebecca Mercerhttps://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.pngRebecca Mercer2019-07-19 11:18:552019-07-19 11:36:4464 Trends in Survival Benefit and Cost-Effectiveness of Anti-Cancer Treatments in Canada
https://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.png00Rebecca Mercerhttps://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.pngRebecca Mercer2019-07-19 11:15:112019-07-19 11:36:4760 A Cost-Utility Analysis of Atezolizumab in the Second-Line Treatment of Metastatic Urothelial Carcinoma
https://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.png00Rebecca Mercerhttps://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.pngRebecca Mercer2019-07-19 11:13:552019-07-19 11:36:5035 Recall for assessment in Quebec breast screening program by type of mammographic findings
https://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.png00Rebecca Mercerhttps://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.pngRebecca Mercer2019-07-19 11:12:552019-07-19 11:36:5334 A review of the Canadian Task Force on Preventive Health Care updated recommendations for breast cancer screening
https://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.png00Rebecca Mercerhttps://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.pngRebecca Mercer2019-07-19 11:11:582019-07-19 11:36:5632 Breast Density in Nova Scotia Women
https://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.png00Rebecca Mercerhttps://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.pngRebecca Mercer2019-07-19 11:11:042019-07-19 11:36:5826 Simulation modeling to inform health system and policy decisions in colorectal cancer screening: a systematic review
https://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.png00Rebecca Mercerhttps://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.pngRebecca Mercer2019-07-19 11:10:142019-07-19 11:37:019 Drug Funding Price Negotiations: Towards Achieving a Balance between Individual and Societal Gains in Health Benefits
https://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.png00Rebecca Mercerhttps://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.pngRebecca Mercer2019-07-19 11:09:352019-07-19 11:37:058 Trends in costs and use of publicly-funded oncology biologics in Ontario.
https://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.png00Rebecca Mercerhttps://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.pngRebecca Mercer2019-07-19 11:09:042019-07-19 11:37:087 The Effectiveness of Ontario’s Generic Pricing Polices for Intravenous Chemotherapy
CCS Research Training Awards 2024December 27, 2023 - 2:37 pm
Patient perspectives of Value Frameworks used to Guide Oncology Treatment DecisionsMay 1, 2021 - 12:27 pm
Connect With Us!